Autoantibodies Against Type I Interferons are a Prominent Feature in SARS-CoV-2 Fatal Disease and Hospitalization
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf514 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Rebeca Linhares Abreu Netto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical, Manaus, Amazonas, Brazil. Hauptthemen laut MEDLINE: COVID-19, Autoantibodies, SARS-CoV-2, Interferon Type I. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Government of the Amazonas State, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Background
Autoantibodies have been implicated as key players in COVID-19 pathogenesis, with evidence of impacting disease severity and poor outcomes.
Methods
We analyzed autoantibody profiles in 435 PCR-confirmed COVID-19 patients in Manaus, Brazil, comparing hospitalized (263) and nonhospitalized (172) individuals, and 37 healthy controls. Twenty autoantibodies and SARS-CoV-2-specific IgA/IgG antibodies were measured using multiplex Luminex® assays from plasma samples collected on days 1, 7, 14, and 28.
Results
Hospitalized patients had significantly higher levels of autoantibodies targeting ACE2, MPO, IFNΩ, IFNα1, and IFNα2 at baseline, with 127 hospitalized patients positive for IFNα1, 161 for IFNα2 and 68 for IFNΩ. Longitudinal analysis revealed progressively increasing levels of anti-ACE2, B2G1, C1q, IFNα1, IFNα2, PADI4, PF4, and PR3 autoantibodies in hospitalized patients; however, the neutralizing capacity of IFNs were not investigated. Survival analysis showed that elevated type I IFN autoantibodies correlated with reduced survival (P = .023). Stronger correlations between autoantibodies and SARS-CoV-2 IgA/IgG were found in severe cases.
Conclusions
In this cohort, autoantibodies were linked to COVID-19 severity and mortality, indicating their potential as biomarkers for patient risk stratification and therapeutic targets. Further research is needed to explore their impact in long-term immune dysregulation and postacute sequelae in COVID-19 survivors. Lay summary COVID-19 affects people differently. Some recover quickly, while others become very sick or die. Scientists have found that some COVID-19 patients develop autoantibodies, or “self-attacking” antibodies. How and which autoantibodies were relevant in COVID-19 remains to be described. This study conducted in Manaus, Brazil, aimed to understand if these autoantibodies contributed to severe COVID-19 and poor survival outcomes. Manaus was one of the hardest-hit regions by the pandemic. We studied 435 COVID-19 patients (263 hospitalized, 172 nonhospitalized), and 37 healthy individuals. Blood samples were collected over 28 days and tested for 20 different autoantibodies and antibodies against the coronavirus using advanced laboratory assays. Hospitalized patients had notably higher levels of 2 specific autoantibodies. Those that block the body's natural antiviral proteins (type I interferons) and ACE2 (helps regulate systemic and local inflammation, and fluid homeostasis). These autoantibodies were strongly linked with severe illness and a higher risk of death, and increased over time. Patients with strong autoantibody responses also had higher levels of antibodies against the virus, suggesting a link between infection and immune self-attack. Autoantibodies were strongly linked to severe COVID-19 and death. Screening for them could help doctors identify high-risk patients early for effective treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Ensino e Pesquisa, Fundação de Medicina Tropical, Manaus, Amazonas, Brazil.
- Escola Superior de Ciências da Saúde, Universidade do Estado do Amazonas, Manaus, Brazil.
- Population Health and Immunity/Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
- Department of Maternal and Child Nursing and Public Health, School of Nursing of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil.
- The University of Melbourne, Department of Medical Biology, Melbourne, Victoria, Australia.
- Saúde Pública, Instituto Leônidas e Maria Deane, FIOCRUZ-AM, Manaus, Brazil.
ORCID-Profile: Rebeca Linhares Abreu Netto, Catherine Chen, Victor Irungu Mwangi, Mariana Simão Xavier, Luiz Gustavo Gardinassi, Emily Marie Eriksson, Nicholas Kiernan-Walker, Marcus Vinícius Guimarães Lacerda, Fernando Fonseca Almeida-Val, Gisely Cardoso de Melo
Förderung
- Government of the Amazonas State
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa do Estado do Amazonas
Zitieren
APA
Linhares Abreu Netto, R., Chen, C., Mwangi, V. I., Padron de Morais, C. E., Simão Xavier, M., Gardinassi, L. G., Eriksson, E. M., Kiernan-Walker, N., Conway, E., Mueller, I., Guimarães Lacerda, M. V., Monteiro, W. M., Fonseca Almeida-Val, F., & de Melo, G. C. (2026). Autoantibodies Against Type I Interferons are a Prominent Feature in SARS-CoV-2 Fatal Disease and Hospitalization. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf514
Vancouver
Linhares Abreu Netto R, Chen C, Mwangi VI, Padron de Morais CE, Simão Xavier M, Gardinassi LG, et al. Autoantibodies Against Type I Interferons are a Prominent Feature in SARS-CoV-2 Fatal Disease and Hospitalization. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf514
BibTeX
@article{LinharesAbreuNetto2026,
author = {Linhares Abreu Netto, Rebeca and Chen, Catherine and Mwangi, Victor Irungu and Padron de Morais, Carlos Eduardo and Simão Xavier, Mariana and Gardinassi, Luiz Gustavo and Eriksson, Emily Marie and Kiernan-Walker, Nicholas and Conway, Eamon and Mueller, Ivo and Guimarães Lacerda, Marcus Vinícius and Monteiro, Wuelton Marcelo and Fonseca Almeida-Val, Fernando and de Melo, Gisely Cardoso},
title = {Autoantibodies Against Type I Interferons are a Prominent Feature in SARS-CoV-2 Fatal Disease and Hospitalization},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf514}
}
EUVIMED